Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.355 USD | +0.64% |
|
+11.61% | +0.21% |
Jul. 08 | Xeris Biopharma Appoints John Shannon as CEO | MT |
Jul. 08 | Xeris Biopharma Holdings, Inc. Announces CEO Changes | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 60% by 2026.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.21% | 349M | C | ||
+62.66% | 854B | C+ | ||
+40.42% | 636B | B | ||
-4.37% | 361B | C+ | ||
+17.16% | 324B | B- | ||
+9.87% | 301B | C+ | ||
+15.66% | 247B | B+ | ||
+4.21% | 230B | A+ | ||
+17.90% | 228B | B- | ||
+14.86% | 177B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- XERS Stock
- Ratings Xeris Biopharma Holdings, Inc.